Analysis of normal mice and transgenic mice carrying a rearranged immunoglobulin p. gene revealed a more complex tissue-specific pattern of Ix gene expression than anticipated from previous observations. Expression of the endogenous Ix locus and the Ix transgene was detected both in lymphoid tissues and in skeletal muscle. Analysis of the expression pattern of Ix transgenes containing intragenic deletions or point mutations in binding sites for Oct transcription factors (OCTA sites) indicated that distinct regulatory sequences control lymphoid-and muscle-specific Ix gene expression. Consistent with previous transfection experiments, Ix gene expression in lymphoid tissues is dependent on the intragenic enhancer and the OCTA site in the promoter. However, neither of these regulatory sequences is required for Ix gene expression in skeletal muscle that is governed by a muscle-specific control region located 3' of the enhancer. An "off-state" of the Ix transgene was observed only in liver and embryonal fibroblasts, whereas enhancer-dependent Ix transgene expression was detected at low levels in other nonlymphoid tissues. From these data we suggest a model for the regulation of tissue-specific Ix gene expression in which a "ubiquitous" competence for basal transcription is up-regulated in lymphoid and muscle tissues by distinct cell type-specific regulatory sequences and down-regulated in liver and fibroblastic cells by putative negative sequence elements.
[Key Words: Immunoglobulin p. gene; cell type-specific gene expression; OCTA sites; transgenic mice] Received November 21, 1990; revised version accepted February 25, 1991. Cell type-specific patterns of gene expression represent genetically stable differences in the transcriptional state of genes. These include both the differences between an "on-state" and an "off-state" of gene expression and the quantitative difference between on-states. Cell type-specific gene expression has been shown to be governed by transcriptional regulators that are specific to one or a few cell types and by differences in the "balance" of positively and negatively acting "ubiquitous" transcription factors (for review, see Herskowitz 1989; Mitchell and Tjian 1989) .
Immunoglobulin genes are expressed and assembled from multiple gene segments by DNA rearrangement specifically in B lymphocytes (for review, see Blackwell and Alt 1988) . Gene transfer of rearranged ~ immunoglobulin heavy-chain (IgH) genes into the mouse germ line (Grosschedl et al. 1984; Storb et al. 1986; Nussenzweig et al. 1987 ) and into cultured lymphoid and fibroblastic cell lines (Gillies et al. 1983; Neuberger 1983; Grosschedl and Baltimore 1985) indicated that lymphoid-specific expression can be uncoupled from gene rearrangement. Lymphoid-specific transcription of rearranged IgH genes was shown to be governed both by the variable region (VH) promoter and by an intragenic enhancer (Banerji et al. 1983; Gillies et al. 1983; Grosschedl and Baltimore 1985; Mason et al. 1985) . Regulatory sequence elements residing in the promoter and the enhancer have been identified by mutational analysis in tissue culture transfection assays (for review, see Calame 1989; Libermann and Baltimore 1991) and by genomic "footprinting" in vivo (Ephrussi et al. 1985) .
The nucleotide sequence 5'-ATGCAAAT, which is referred to as the OCTA site, is present in both the VH promoter and the intragenic enhancer of rearranged heavy-chain immunoglobulin genes. The OCTA site in the promoter confers a 5-to 10-fold higher transcriptional activity upon a heterologous promoter in B-lymphoid versus fibroblastic cell lines (Wirth et al. 1987) . This sequence has been demonstrated to interact in vitro with a family of nuclear factors, collectively termed Oct OCTA-dependent and -independent It gene expression proteins or octamer transcription factors (OTFs) Staudt et al. 1986; Fletcher et al. 1987; Scheidereit et al. 1987; Sch61er et al. 1989) . One member of this family, termed Oct-2, can be detected in high abundance in lymphoid B-cell lines, in lower abundance in several lymphoid T-cell lines, and in some nonlymphoid tissues such as brain and kidney, but is absent from fibroblastic cell lines and most nonlymphoid tissues (Staudt et al. 1986; Sch61er et al. 1989; Cockerill and Klinken 1990) . The OCTA site has also been shown to interact in vitro with the ubiquitous Oct-1 transcription factor Fletcher et al. 1987; Scheidereit et al. 1987; LeBowitz et al. 1988; Johnson et al. 1990 ). Oct-i, however, appears to be less effective than Oct-2 at stimulating transcription from a promoter containing an OCTA-related site in transfection assays (Tanaka and Herr 1990) . The heptanucleotide sequence 5'-CTC-ATGA, termed Hepta site, has been identified as an additional low-affinity binding site for Oct-1 and Oct-2 in vitro (Landolfi et al. 1988; Kemler et al. 1989; Poellinger et al. 1989) . The Hepta site is found in many but not all V H promoters 5' to the OCTA site, which appears to be necessary for occupancy of the Hepta site by Oct proteins (Poellinger et al. 1989) .
The intragenic ~ enhancer encompasses an OCTA site and other factor-binding sites, termed the ~B site, the E box, the ~EI-~E5 motifs, and enhancer core sequences (Ephrussi et al. 1985; Peterson et al. 1986; Sen and Baltimore 1986; Lenardo et al. 1987; Araki et al. 1988) . The E box and the ~E5/E2 and ~E3 sites have been shown to interact with ubiquitous factors in vitro (Murre et al. 1989; Beckmann et al. 1990; Henthorn et al 1990; Roman et al. 1990 ). The ~B site is, to date, the only other site in the enhancer that generates a B-cell-specific "footprint" in nuclear extracts and is implicated in contributing to B-cell specificity of enhancer function (Libermann et al. 1990; Nelsen et al. 1990 ). The cell typespecific function of the ~ enhancer in lymphoid versus fibroblastic cells was also shown to involve negative regulation because deletions of nucleotide sequences within and adjacent to the enhancer allow, at least in part, for ~ enhancer function in fibroblastic cells (Kadesch et al. 1986; Imler et al. 1987; Weinberger et al. 1988; Scheuermann and Chen 1989) .
In this study we introduced rearranged wild-type and mutated ~ genes into the mouse germ line to examine the role of Oct factor-binding sites and other regulatory sequences in the context of the intact gene and the whole animal. The analysis of the expression of various transgenes in lymphoid tissues was consistent with previous tissue culture transfection assays. However, the tissue-specific pattern of transgene expression was more complex than anticipated. Instead of a simple on-state in lymphoid tissues and an off-state in nonlymphoid tissues, the ~ transgene was found to be expressed at a high level both in lymphoid tissues and in skeletal muscle. This "dual" tissue specificity was also demonstrated for the endogenous ~ locus. Furthermore, ~ transgene expression at a low level was detected in many but not all nonlymphoid tissues. We show that this complex pattern of ~ gene expression is governed by nonoverlapping regulatory sequences of distinct tissue specificities.
Results

Gene expression in lymphoid tissues and skeletal muscle
Transgenic mice carrying rearranged ~ heavy-chain genes were generated by microinjection of vector-free DNA into fertilized eggs and surgical reimplantation into foster mothers (see Materials and methods). Expression of a rearranged wild-type ~ transgene was examined by analyzing total RNA from various tissues of the mouse line 4 for the presence of correctly initiated ~T transgene transcripts (Fig. 1A) . As expected, S1 nuclease protection assays of tissue RNA indicated abundant ~T transcripts in lymphoid tissues (spleen and thymus). The size of the protected fragment (62 nucleotides) indicated faithful initiation at the site mapped for this promoter in a rearranged endogenous gene (Grosschedl and Baltimore 1985) . Surprisingly, strong expression of the ~ transgene was also observed in skeletal muscle. In addition, lowlevel expression was detected in kidney, brain, salivary gland, lung, and heart. This expression pattern was confirmed by the analysis of mice from two additional lines carrying the wild-type p, transgene (see Figs. 3 and 5, below) . To demonstrate that the ~T transcripts detected in skeletal muscle are not derived from contaminating B lymphocytes, we examined the RNA for the presence of endogenous K immunoglobulin transcripts by hybridization with a cK constant region probe. No K transcripts were detectable in the RNA from skeletal muscle. However, salivary gland and lung contained K transcripts, indicating some contamination with B lymphocytes (Fig.  1A, middle) . To demonstrate that the quantity and integrity of the RNA is similar for each sample, the 18S rRNA was stained with ethidium bromide (Fig. 1A, bottom) . From these data we conclude that the p~ transgene is selectively expressed in lymphoid and skeletal muscle tissues and that the ~b T transcripts in both tissues initiate at the same site in the V H promoter.
To examine whether this unexpected expression of the transgene in skeletal muscle was also true for the endogenous ~ locus, we analyzed RNA from tissues of a normal C57BL6 mouse by S1 nuclease protection assays with a c~ constant region probe. This probe allows the detection of transcripts from both rearranged and unrearranged ~ genes. Indeed, c~ transcripts were detected in spleen, thymus, and also in skeletal muscle (Fig. 1B) . The number of c~ transcripts in thymus and skeletal muscle was significantly lower than in spleen, most likely because of a lack of complete gene rearrangement (Kemp et al. 1980) . Like the ~L T transcripts, the endogenous ~ transcripts in skeletal muscle also appear to be generated by transcription of the ~ gene in this tissue rather than by lymphocyte contamination by the following arguments: First, RNA from skeletal muscle did not contain any detectable K transcripts (Fig. 1B, bottom) . Second, the analysis of size-fractionated transcripts from skeletal muscle indicated that the size of these endogenous transcripts is 1.8 kb {Fig. 1C). This is different from both the 2.4-and 2.7-kb ~ m R N A found in spleen and the multiple c, transcripts derived from the unrearranged or incompletely rearranged ~ gene in thymus [Fig. 1C; Nelson et al. 1983) . The endogenous ~ transcripts in skeletal muscle also differ from the transgenic ~T transcripts, indicating that the endogenous ~ gene is not rearranged in skeletal muscle {Fig. 1C). Expression of the endogenous ~ locus in skeletal muscle was detected in other mouse strains as well, although the level of expression varied over a broad range. In C57BL6, SIL, and C3H mice, endogenous c~ transcripts in skeletal muscle were present at a level approximate.ly fivefold lower than that in thymus; whereas in skeletal muscle from BALB/c mice, the c~ transcripts were barely detectable {data not shown). Because the expression of the rearranged ~ transgene in several nonlymphoid tissues is -50-fold lower than in skeletal muscle, the sensitivity of the S1 protection assay is not sufficient to determine whether this low-level expression of the ~ transgene reflects a similar transcriptional state of the endogenous gene or whether the transgene lacks regulatory sequences that prevent expression of the endogenous ~ gene in these tissues. Taken together, these data show that both the endogenous ~ gene and rearranged ~ transgenes exhibit a previously unknown dual tissue specificity and are expressed in lymphoid and muscle tissues.
Role of Oct-binding sites for t ~ gene expression in lymphoid tissues and skeletal muscle
The high level of ~ gene expression in lymphoid tissues and in skeletal muscle raised the question as to whether both types of tissues utilize the same set or a distinct set of regulatory sequences in the ~ gene. Because the Octbinding sites have been shown previously to be involved in lymphoid-specific gene expression, we were particularly interested in comparing the role of the OCTA sites for transgene expression in lymphoid and skeletal muscle tissues.
We generated transgenic mice carrying rearranged genes with point mutations in Oct-binding sites {Fig. 21. The expression of the transgenes was analyzed in founders that were shown to transmit the transgene in a Mendelian manner or in progeny to avoid the analysis of animals mosaic for the transgene. The wild-type W transgene was expressed in spleen of three independent mouse lines at high levels ( Fig. 3, top) . The level of expression appeared to be fairly independent of the chromosomal site of the integrated transgene. As an internal control for the relative number of B lymphocytes in each tissue sample and to demonstrate the integrity of the RNA preparation, we determined the number of transcripts of the B-lymphocyte-specific endogenous mb-1 gene (Sagakuchi et al. 1988) or K gene. Similar numbers of mb-1 or K transcripts were detected in the individual tissue samples (data not shown). In addition to spleen, we analyzed lymphoid-specific expression of the transgene in thymus for the following reasons: First, thymus contains primarily cells that represent the T-cell lineage. Second, T cells do not synthesize endogenous ~ protein because of a lack of complete immunoglobulin gene rearrangement (Kurosawa et al. 1981; Reth and Alt 1984) . As a consequence, expression of the transgene cannot be influenced by endogenous ~ protein. Third, the abundance of Oct-2 in several T-cell lines is substantially less than that observed in B-cell lines (Cockerill and Klinken 1990) . Despite these differences, we find, in agreement with previous observations (Grosschedl et al. 1984) , that the wild-type ~ transgene is equally well expressed in both lymphoid tissues (Fig. 3, middle) .
Mutation of the OCTA site in the promoter (Ov) reproducibly decreased the number of specific ~. transcripts in both spleen and thymus by a factor of 20--30 (Fig. 3, top and middle) . The O r -O~-double mutation of the OCTA sites in both promoter and enhancer did not further reduce the number of specific [_L T transcripts, suggesting either functional redundancy of the OCTA site in the enhancer or a functional interaction between both OCTA sites. To examine these possible interpretations, we analyzed transgenic mice that carry a ~ transgene with a single mutation in the OCTA site of the enhancer (Or-). Four of five mouse lines expressed the mutated transgene at a similar level as the wild-type gene. The fifth mouse line, 642, expressed the O r -transgene at a 10-fold lower level, indicating some variability in the transcriptional effect of this mutation. Taken together, however, these results indicate that expression of the ~ transgene in lymphoid tissues is virtually independent of the OCTA site in the enhancer but is to a large extent dependent on the OCTA site in the promoter. The low-affinity Oct-binding site in the promoter (Hv) is also dispensable for transgene expression in lymphoid tissues because the H v -mutation did not significantly decrease the number of ~T transcripts in two mouse lines.
In skeletal muscle these mutations have little or no transcriptional effects (Fig. 3, bottom) . Expression of the O r -mutant transgene is indistinguishable from the wild-type gene in two mouse lines (817 and 801) and only fourfold lower in line 811. These data indicate that the OCTA site in the promoter is virtually dispensable for the high-level expression of the ~ transgene in skeletal ation, and the individual mouse, respectively.
LINE ~
The letter F after the number of the mouse line indicates the founder animal. Only founders who o~ transmitted the transgene in a Mendelian mannet were included in the analysis. The number in ~-parentheses refers to the approximate copy num-:I: ber of the transgene as determined by DNA blot analysis. For the analysis of transgene expres-
sion, the mice were sacrificed between the ages LINE ~.
"7, d~ of 8 and 12 weeks. The integrity and quantity of ~ ~" "-each RNA preparation from spleen and thymus '~ to were confirmed by S1 nuclease protection assays tu ¢~ with DNA probes that detect endogenous mb-1 .~ (Sagakuchi et al. 1988) 
" "7, ~t T muscle. The m u t a t i o n of the Hp site in the promoter had no transcriptional effect in m o u s e line 716; however, it decreased transgene expression by a factor of 10 in m o u s e line 717. The small n u m b e r of H p -transgenic mice and the variability of the transcriptional effect of the H p -mutation, however, does not allow us to determ i n e the precise functional importance of this site for Ix gene expression in skeletal muscle.
In conclusion, the O C T A site in the promoter is required for Ix gene expression only in l y m p h o i d tissues but not in skeletal muscle, confirming its role as an important d e t e r m i n a n t of lymphoid-specific gene expression. In contrast, the O C T A site in the enhancer is virtually dispensable for gene expression in both tissues, suggesting either that the OE-m u t a n t enhancer retains full activity because of a functional redundancy of its factor-binding sites or that other regulatory sequences in the gene can compensate for the m u t a t e d enhancer.
A n intragenic muscle-specific control region in the Ix gene
The O C T A independence of Ix transgene expression in skeletal muscle suggests that the gene contains other regulatory sequences that allow for a high-level expression of the O r -m u t a n t transgene in this tissue. Because these regulatory sequences m a y also be involved in the expression of the unrearranged endogenous Ix gene in skeletal muscle, we searched for t h e m in the large intron preceding the cw constant region. To examine w h e t h e r such sequences reside w i t h i n the intragenic enhancer, we deleted from the intact Ix gene the 0.6-kb ScaI-EcoRI D N A fragment comprising all nuclear factor-binding sites as detected by in vivo footprinting of genomic D N A (Ephrussi et al. 1985 ) (&12/18; Fig. 4A ). Three transgenic m o u s e lines carrying the m u t a n t A12/18 Ix transgene did not express the gene at any detectable level in l y m p h o i d tissues (Fig. 4B) , confirming the complete dependence of Ix gene transcription on the enhancer. Surprisingly, expression of the m u t a n t transgene in skeletal muscle of mouse line 313 was reduced only twofold and, in lines 301 and 327, fourfold. This indicates that Ix gene expression in this tissue is largely independent of the IgH enhancer.
A n o t h e r m u t a n t was generated by deleting a 2.9-kb HpaI-XbaI D N A fragment located 3' of the IgH enhancer (A25/54, Fig. 4A ). This deletion had little effect on transgene expression in spleen and t h y m u s of m o u s e lines 210 and 222 (Fig. 4B) . However, transgene expression in skeletal muscle was reduced 50-fold to a level similar to that detected in most other n o n l y m p h o i d tissues (see Figs. 4B, and 5) . From these data, we conclude that this intragenie control region allows for Ix gene expression in the absence of lymphoid-specific regulators and independent of the IgH enhancer and the O C T A site in the promoter. Thus, distinct and nonoverlapping regulatory sequences govern I~ transgene expression in l y m p h o i d tissues and skeletal muscle.
The Ix enhancer is functional in m a n y but not all nonlymphoid tissues.
In addition to the high-level expression in l y m p h o i d tis- ~t T Figure 4 . Identification of an intragenic muscle-specific control region. (A) Structure of internal deletions. The mutation A12/18 deletes a 0.6-kb ScaI-EcoRI DNA fragment comprising the enhancer from the ~ gene. The numbers of the mutation refer to onehundredth of the nucleotide positions of the 5' and 3' boundary of the deletion with respect to the mRNA start site as + 1 (see also Fig. 1 ). The mutation A25/54 deletes a 2.9-kb HpaI-XbaI DNA fragment 3' of the intragenic ~ enhancer. (B) S1 nuclease protection assay detecting ~T transcripts in 3 ~g of total RNA from spleen, thymus, and skeletal muscle of mice carrying wild-type or mutated transgenes. The integrity and quantity of the RNA preparations from spleen and thymus were confirmed by S 1 nuclease protection assay with a probe detecting endogenous rob-1 or K transcripts as described in Fig. 3 (data not shown) . Adjusting for the numbers of mb-1 transcripts as control, the numbers of transgenic ~. 1, T transcripts in spleen RNA from mice 210-2-2 and 222-1-6 appear to be under-represented by a factor of 5. sues and skeletal muscle, the wild-type ~ transgene was expressed at a low level in several nonlymphoid tissues (mouse lines 4 and 19; Fig. 5 ). Quantitation of input total RNA was determined by UV spectrophotometry and confirmed by ethidium bromide staining of 18S rRNA (data not shown). To control for blood and lymph node contamination, the various RNA samples were also hybridized with a cK constant region probe detecting endogenous K transcripts (data not shown). K transcripts were absent in most of the RNA preparations from nonlymphoid tissues and were only detected at low levels in some RNA preparations from salivary glands. Expression of the ~ transgene in kidney, brain, and salivary gland was demonstrated further by the analysis of the Opmutant transgene. The Ov-mutation did not significantly affect I~ transgene expression in these nonlymphoid tissues, whereas ~J*T levels in spleen and thymus were drastically reduced (mouse lines 817 and 810; Fig.   5 ). The mutant A25/54 transgene, lacking the putative muscle-specific control region, is also expressed at a low level in skeletal muscle (mouse lines 210 and 222; Fig. 5 ). These expression patterns raise the question as to whether the intragenic ~ enhancer may be active in nonlymphoid tissues.
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OCTA-dependent and -independent I~ gene expression
We examined the function of the enhancer in nonlymphoid tissues by analyzing the expression of the A12/18 transgene in liver, kidney, brain, salivary gland, and skeletal muscle (mouse lines 301 and 313; Fig. 5 ). Neither of the two mouse lines analyzed expressed the enhancerless transgene in any of the tissues except in skeletal muscle. This suggests that the enhancer governs both the high-level expression in lymphoid tissues and the low-level expression in nonlymphoid tissues. In liver, however, no ~J~T transcripts can be detected in any of the transgenic mice indicating that the I~ enhancer is nonfunctional in this tissue. The activity of the ~ en-Cold Spring Harbor Laboratory Press on August 14, 2017 -Published by genesdev.cshlp.org Downloaded from J e n u w e i n and G r o s s c h e d l ~w t F i g u r e 5. Tissue-specific pattern of expression of mutated ~ transgenes. S1 nuclease protection assay detecting transgenic ~T transcripts in 12 ~ O~ ~g of total RNA from spleen (SPl, thymus (THI, liver (LI), kidney (KIJ, brain (BR), salivary gland (SG), and skeletal muscle (SM) of mice carrying a wild-type or a mutated p~ transgene. For each transgene, two independent mouse lines were analyzed. To test for the presence of contaminating lymphocytes in the tissue preparations from kidney, brain, and salivary gland, S1 nuclease protection assays with a c~ DNA probe detecting endogenous K transcripts were per-,o~ formed (data not shown). Endogenous K transcripts were found only at low abundance in total RNA preparations from salivary glands of transgenic mice 19-1-4, 801-1-9, 604-1-1 and 631-1-1 and at higher abundance in the RNA preparation from salivary gland of mouse line 918-1-5. K transcripts were also present at low abundance in total RNA preparations from kidneys of transgenic mice 817-1-1, 918-1-5, and 631-1-3. The integrity and quantity of the RNA preparations from the various tissues were con-A 25/54 firmed by staining of 18S rRNA with ethidium bromide (data not shown). Grosschedl, unpubl.) . Taken together, these data suggest that the ~ enhancer is functional in m a n y but not all nonlymphoid tissues. Moreover, the OCTA site in the enhancer contributes to ~ gene expression in nonlymphoid cells, which indicates that this site may be functionally distinct from the lymphoid-specific OCTA site in the promoter.
D i s c u s s i o n
Our study suggests that the tissue-specific expression pattern of the ~ immunoglobulin gene is more complex than consisting of a simple on-state in lymphoid tissues and an off-state in all nonlymphoid tissues. We detect expression of a rearranged ~ transgene and the endogenous p. locus not only in lymphoid tissues but also in skeletal muscle. In addition, we observe ~ transgene expression at a low level in m a n y but not all nonlymphoid tissues. Therefore, transgene expression, falls into four categories (for schematic summary of the data, see Fig.  6 ). First, expression in lymphoid tissues at a high level is dependent on the intragenic enhancer and the OCTA site in the promoter. Second, expression in skeletal muscle is detected at a level comparable to that in lymphoid tissues and is governed by a muscle-specific control region (MCR) located 3' of the enhancer. Both the enhancer and the OCTA site in the promoter are virtually dispensable for ~ gene expression in skeletal muscle. Although the ~ enhancer is nonessential for transgene expression in skeletal muscle, it appears to be functional (see below for discussion). Third, expression at a 50-fold lower level is observed in brain, kidney, and salivary gland. This low-level expression is dependent on the p. enhancer but is independent of the OCTA site in the promoter. Therefore, the enhancer is found to be functional in several nonlymphoid tissues, although its activity in lymphoid tissues appears to be 3-to 10-fold higher, possibly due to a lymphoid-specific sequence element (LSE) (see below for discussion). Fourth, liver and embryonic fibroblast cells do not express the transgene at any detectable level and appear to represent a true off-state of the gene. Active repression of enhancer function by negative regulatory elements (NR), previously identified in tissue culture (Kadesch et al. 1986; Imler et al. 1987; Weinberger et al. 1988; Scheuermann and Chen 1989) , m a y prevent p~ transgene expression in these tissues.
OCTA-dependent and OCTA-independent tz gene transcription
Transcription of the rearranged p~ transgene in lymphoid tissues of transgenic mice is largely dependent on the OCTA site in the promoter. In contrast, the mutation of the OCTA site in the promoter has virtually no effect on transcription in any of the analyzed nonlymphoid tissues. Our data do not distinguish between a nonfunctional and a nonessential Ov site in nonlymphoid tissues. However, the observation that both the high-level expression of the tx gene in skeletal muscle and the lowlevel expression in other nonlymphoid tissues are independent of the Op site argues for a lack of function rather than a functional redundancy. The question arises as to whether the difference in the OCTA-dependent promoter function in lymphoid versus nonlymphoid tissues can be explained in the framework of the tissue distribution and transcriptional activation potential of Oct-1 and Oct-2. The OCTA-independent promoter function in skeletal muscle suggests that the ubiquitous Oct-1 protein by itself is not sufficient to stimulate promoter activity. Oct-2, by itself, however, may also be insufficient to account for lymphoid-specific expression. Recent observations indicated that the expression of the endogenous p, gene in tissue culture cells does not correlate with the abundance of Oct-2 protein (Cockerill and Klinken 1990) . Likewise, the OCTA dependence of ~ transgene expression in spleen and thymus is similar, despite a large difference in the abundance of Oct-2. Analysis of nuclear extracts from rat spleen and thymus for the presence of Oct proteins by electrophoretic mobility-shift assays indicated that Oct-2 can be detected in thymus at -5 % of the level detected in spleen (A. Amsterdam and R. Grosschedl, unpubl.) . Taken together, these data can, in principle, be accounted for by at least two explanations. First, a small or even an undetectable amount of Oct-2 is sufficient for conferring OCTA-dependent promoter function. We consider this as unlikely because the dependence of p, transgene expression on a functional Op site increases during B-cell differentiation and by stimulation of splenocytes with bacterial lipopolysaccharide (T. Jenuwein and R. Grosschedl, unpubl.) . Both of these conditions were shown previously to increase the abundance of Oct-2 (Staudt et al. 1986 ). Instead, we favor a second view according to which an interaction of the ubiquitous Oct-1 protein with a putative lymphoid-specific factor would enhance the potential of Oct-1 at stimulating transcription from the Via promoter in spleen and thymus. For example, the interaction between the viral protein VP16 and Oct-1 results in the formation of a complex that is more effective at stimulating transcription from a reporter gene containing an OCTA-related binding site than Oct-1 itself (Stern et al. 1989 ). According to this scheme, Oct-1 in combination with the putative lymphoid-specific activator would govern OCTA-dependent
promoter function in unstimulated or immature B lymphocytes and in T lymphocytes, whereas Oct-2 would up-regulate V H promoter function during B-cell differentiation and upon cell stimulation.
Another question arises as to the functional role of the OCTA site in the Ix enhancer. The OCTA site in the Ix enhancer (OE) is dispensable for expression in both lymphoid tissues and skeletal muscle. In other nonlymphoid tissues, however, this site appears to be involved in lowlevel Ix transgene expression. The contribution of the OE site to basal ~ enhancer function is most evident in the context of a mutant Or-promoter and in tissues that lack lymphoid-or muscle-specific regulators. Possibly, functional differences of the OE and O v sites result from the binding of distinct Oct proteins. Consistent with this interpretation, OCTA-binding proteins, different from Oct-l, have been identified in nuclear extracts from several nonlymphoid tissues (Sch61er et al. 1989) . Moreover, biochemical evidence suggests that the OE site, but not the Op site, can interact with a protein, termed Oct-2B, which is related to Oct-2 but gives a distinct trypsin digestion pattern (Schreiber et al. 1988; Mfiller-Immerglfick et al. 1990 ).
IgH enhancer function in multiple cell types
With the exception of skeletal muscle, transcription of the rearranged ~ gene is completely dependent on enhancer sequences. Previous transfection experiments indicated that the IgH enhancer is functional in lymphoid cell types but not in fibroblastic cells (Banerji et al. 1983; Gillies et al. 1983; Lenardo et al. 1987} . Our transgenic mouse experiments extend the analysis of IgH enhancer function to other cell types as well and indicate that the Ix enhancer not only govems gene expression in lymphoid tissues but also in many nonlymphoid tissues.
The activity of the enhancer, however, appears to be 3-to 10-fold higher in lymphoid tissues than in brain, kidney, and salivary gland, as determined by the different expression levels of the Or-transgene in mouse lines 817 and 801. This tissue specificity is even more pronounced with Or-OE-transgenes, suggesting that other putative regulatory sequences, in addition to the OCTA sites, contribute to lymphoid specificity of Ix gene expression. Although the identity of these sequences, referred to as LSEs {see Fig. 6 ), is currently unknown, they are likely to reside in the ~ enhancer. One candidate for the LSE is the IXB site, which recently has been shown to confer B-cell-specific expression on a heterologous gene {Libermann et Nelsen et al. 1990} . However, it is unlikely that this site is the only LSE, because a mutant Ix transgene that lacks both a functional OCTA site and ~B site in the enhancer is expressed in lymphoid tissues of two transgenic mouse lines at a level similar to the wild-type gene IT. Jenuwein and R. Grosschedl, unpubl.) . Other sequences in the Ix enhancer, such as the E2/E3 boxes {Cook and Neuberger 1990), or the recently identified ~r box (Libermann et al. 1990} , may also contribute to lymphoid-specific gene expression.
Although the v-enhancer does not appear to be re-
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GENES & DEVELOPMENT quired for transgene expression in skeletal muscle, the enhancer is functional on the basis of the following observations: First, expression of the A25/54 transgene was decreased in skeletal muscle to a low level, similar to that detected in the other nonlymphoid tissues. Because the A25/54 mutation affected V-transgene expression only in skeletal muscle, this indicates a tissue-specific function of the deleted regulatory sequences. Second, a deletion mutant that lacks both the IgH enhancer and the muscle-specific control region is not expressed at any detectable level in this tissue {A. Darveau and R. Grosschedl, unpubl.) . The transcriptionally inactive state of the Ix transgene in liver and fibroblastic cells raises the question as to whether the enhancer is nonfunctional or repressed in these cell types. Previous transfection experiments demonstrated that the lack of Ix enhancer function in fibroblasts is due, at least in part, to negatively acting regulatory sequences located adjacent to the enhancer (Imler et al. 1987; Scheuermann and Chen 19891 or located between the E1 and E2 motif (Weinberger et al. 19881 . In addition, sequences that contribute to enhancer function in lymphoid tissues, such as the OCTA site, the IXB site, and the E5/E2 box, were also shown to be targets for negative regulation {Yu et al. 1989; Henthom et al. 1990 ; Libermann et al. 1990) . Whatever sequences govern the negative control of enhancer function, our analysis in transgenic mice indicates that the transcriptionally inactive state of the g. transgene is restricted to specific nonlymphoid cell types.
Complex tissue specificity of tz gene expression
In this study we show that both the endogenous ~ gene locus and a rearranged Ix transgene are expressed in lymphoid tissues and in skeletal muscle. Furthermore, we have identified an intragenic region in the V-gene that govems high-level expression of the ~ transgene in skeletal muscle. This pattem of tissue-specific expression of the ~ gene is more complex than that anticipated from previous observations. Mouse germ-line transformations with murine Ix genes linked to bacterial plasmid sequences did not exhibit transgene expression in skeletal muscle {Grosschedl et al. 1984; R. Grosschedl, unpubl.I. Possibly, plasmid sequences interfere with Ix gene expression in skeletal muscle. Indeed, bacterial plasmid sequences have been shown to inhibit the expression of a microinjected skeletal muscle actin gene in transgenic mice (Shani 1986} .
The biological significance of a MCR located in the immunoglobulin Ix gene is unclear. It is unlikely that the endogenous c~ transcripts in skeletal muscle are translated because similar transcripts that are generated from the unrearranged Ix gene in B and T lymphocytes fail to give rise to protein {Nelson et al. 1983; Lennon and Perry 1985}. Moreover, the broad range in the abundance of c~ transcripts in skeletal muscle of different mouse strains seems to be inconsistent with an important biological role for these transcripts. Possibly, the intragenic MCR directs muscle-specific expression of a distinct gene Cold Spring Harbor Laboratory Press on August 14, 2017 -Published by genesdev.cshlp.org Downloaded from nested within the immunoglobulin heavy-chain locus. This gene-within-a-gene arrangement has now been observed for several gene loci (Levinson et al. 1990; Viskochil et al. 1990 ).
The presence of endogenous c~ transcripts in skeletal muscle indicates a lack of stringent control of lymphoid specificity of transcription. However, in the absence of functional gene rearrangement, no ~ protein can be synthesized. Thus, the control of immunoglobulin gene rearrangement appears to provide another mechanism to confer cell type specificity on the ~ gene. Recently, the RAG-1 and RAG-2 genes, which are involved in the rearrangement of immunoglobulin genes, were shown to be expressed only in lymphocytes (Oettinger et al. 1990) . From the previous observation of high-level expression of a rearranged ~ transgene in thymus, we concluded that rearrangement plays an important role in determining the B-versus T-lymphocyte specificity of expression (Grosschedl et al. 1984) . We can now extend the role of gene rearrangement as an important restrictive process for cell type-specific immunoglobulin gene expression to nonlymphoid tissues as well.
In conclusion, our study of the regulation of ~ transgene expression suggests that the ~ gene has a ubiquitous competence for transcription, as evidenced by lowlevel expression in many tissues. This basal expression is up-regulated in lymphoid and muscle tissues by distinct regulatory sequences. Moreover, putative negative sequence elements may be necessary to down-regulate the basal expression and to confer the inactive transcriptional state that is observed only in specific cell types. Thus, the plethora of regulatory information appears to be required for directing the complex tissue-specific expression pattern of the ~ gene in the whole animal.
Materials and methods
Construction of point mutations
The DNA construct (p~) harboring the rearranged wild-type gene has been described (Grosschedl et al. 1984) . For the generation of point mutations in the various Oct-binding sites, the XbaI-EcoRI DNA fragment comprising the ~ enhancer (Fig. 2) between nucleotide position + 1085 and + 1765 relative to the transcription start site or the HindIII-EcoRV DNA fragment containing V H promoter sequences (Fig. 2) between nucleotide position -950 and -18 was subcloned into the polylinker of Bluescript M13KS-and Bluescript M13KS + (Stratagene), respectively. Site-directed mutagenesis was accomplished by a modification of the method of Kunkel (1985) . Plasmid DNA was transformed into Escherichia coli strain CJ236. Coinfection with bacteriophage M13R408 resulted in the production of single-stranded uracil-containing plasmid DNA. Oligonucleotides containing the desired point mutations in the Oct-binding sites were annealed to the single-stranded plasmid DNA and used as primers for synthesis of the second strand. The DNA was transformed into E. coli strain HB101, and mutants were identified by sequencing supercoiled DNA obtained from individual transformants. For each mutation procedure, ~>50% of transformants carried a mutated plasmid. The mutated enhancer and promoter DNA fragments were then transferred into p~, and the presence of the mutated factor-binding sites was confirmed by sequencing the respective regions of interest in the final DNA construct.
Construction of deletion mutations
To generate the ~ enhancer deletion mutant A12/18, the Eco-RV-SacI fragment from p~, comprising the rearranged VDJ variable region and the intragenic ~ enhancer (Fig. 2) between nucleotide positions -18 and + 2592, was subcloned into the polylinker of Bluescript M13KS+ (Stratagene). The recombinant DNA was cleaved with EcoRV and ScaI, and the fragment between nucleotide positions -18 to + 1236 was isolated. This fragment was inserted into EcoRV/EcoRI-cleaved and bluntended ~z vector DNA and analyzed for its correct orientation. The resulting DNA construct lacks ~ enhancer sequences between nucleotide position + 1236 to + 1765 (Fig. 4) .
To generate the deletion mutant A25/54, the EcoRI-BamHI fragment from pp~, containing intragenic and }z constant region exon sequences (Fig. 2) between nucleotide positions + 1765 and + 6430, was subcloned into the polylinker of Bluescript M13KS + (Stratagene). The recombinant DNA was cleaved with XbaI, the 5' ends were filled in with Klenow DNA polymerase (Boehringer Mannheim), and the DNA was digested further with BglII. The fragment between nucleotide positions + 5375 to + 6120 was isolated. This fragment was inserted into HpaI/ BglII-cleaved ~ vector DNA. The resulting DNA construct lacks ~ intragenic sequences between nucleotide positions +2586 to +5375 (Fig. 4) .
Generation of transgenic mice
Plasmids containing the rearranged ~ gene were cut with SalI and XhoI, and the ~ gene insert was purified from bacterial vector sequences by gel electrophoresis. Linear ~ DNA was diluted to 3 ~g/ml and introduced into the germ line of mice by microinjection of fertilized C57BL6 x SJL F 2 mouse eggs as described (Hogan et al. 1986} . Transgenic mice were identified by blot analysis of tail DNA. On the average, -15% of babies born were transgenic.
RNA analysis
For the detection of transgenic V H transcripts ([J'T), 3 or 12 ~g of total RNA, isolated from various tissues as described (Grosschedl et al. 1984) , was hybridized in the presence of carrier RNA (final amount of RNA adjusted to 15 ~g) at 37°C with a single-stranded, 32P-5'-end-labeled DNA probe. Quantitation of total RNA was determined by UV spectrophotometry and confirmed by ethidium bromide staining of 18S rRNA. The DNA probe was prepared by extending an oligonucleotide primer complimentary to nucleotide sequences between + 45 and + 62 from the RNA 5' end with Klenow DNA polymerase (Boehringer Mannheim). RNA-DNA hybrids were digested with 20 units of S1 nuclease (Pharmacia) at 37°C, and the protected 62-bp nucleotide fragment was separated on a sequencing gel and visualized by autoradiography. Quantitation of RNA levels was determined by densitometric scanning of autoradiograms. The RNA analysis by S 1 nuclease protection assays was performed multiple times with each sample.
For the detection of endogenous c~ transcripts, 6 ~g of total RNA was hybridized in the presence of 6 ~g of carrier RNA at 48°C with a strand-separated, 32p-5'-end-labeled DNA fragment comprising the exon/intron boundary of the first ~ constant region exon. The probe for the detection of endogenous K transcripts was a strand-separated, 32p-5'-end-labeled DNA fragment comprising sequences from the K constant region exon.
The probe for the detection of endogenous rob-1 transcripts was a 32p-5'-end-labeled DNA fragment protecting nucleotide positions from + 3 to + 245 of the m b-1 gene (Sagakuchi et al. 1988) .
For the RNA blot analysis, 12 ~g of total RNA was separated on a 1.2% agarose-2.2 M formaldehyde gel in the presence of ethidium bromide at 2 ~g/ml. The RNA was transferred to a nylon filter and hybridized with a gaP-labeled nick-translated DNA probe comprising the first ~ constant region exon. RNA-DNA hybrids were visualized by autoradiography.
